ERBB2 and neoplasm: Translation of these results to a pharmacological scenario has illustrated that combining daraxonrasib with afatinib, an irreversible EGFR/HER2 tyrosine kinase inhibitor, and SD36, a selective STAT3 PROTAC, also led to robust tumor regression without evidence of tumor resistance [22].